March 26, 2007 08:00 ET

A New Angle to Treat Hard-To-Reach Acne

DUSA Pharmaceuticals Launches ClindaReach™

WILMINGTON, MASSACHUSETTS--(CCNMatthews - March 26, 2007) - There is a new angle of attack on body acne in places that are hard-to-reach and treat, such as the back. ClindaReach™, a revolutionary easy to use treatment that packages a topical antibiotic with an ergonomically designed applicator to treat hard-to-reach acne, was launched this week by DUSA Pharmaceuticals, Inc. (NASDAQ GM:DUSA).

ClindaReach is a prescription product consisting of clindamycin, a frequently prescribed topical antibiotic that is used to treat acne, packaged with a unique EasyReach™ applicator to provide an easy and efficient method for treating hard to reach acne. ClindaReach is initially being introduced to dermatologists in the United States and is now available to pharmacies.

"Until now, individuals were limited in their ability to effectively apply topical medication on hard-to-reach acne afflicted areas of their body, such as the back. My patients end up contorting their bodies for extended reach, missing areas in need of medication, or relying on another person to help apply it," commented Mark S. Nestor, M.D., Ph.D.(i), clinical associate professor of dermatology and cutaneous surgery, University of Miami, Miller School of Medicine, and dermatologic and laser surgeon practicing in Aventura, Florida.

"As with any condition, treatment compliance is essential. When patients find it difficult to maintain a treatment regimen, they stop. ClindaReach is unique because of its simplicity. I love this product!

It takes a proven acne medication, which is packaged with a light-weight wand that makes reaching the entire surface of the back much easier. To me, this is a product we've needed for our patients for a very long time."

Nearly 50 million people in the United States suffer from acne and almost half of those people suffer from back acne.

Bob Doman, DUSA's President and Chief Operating Officer said, "We recognized the challenges patients with hard-to-reach acne experience and developed ClindaReach to meet this compelling need. ClindaReach is our first product launch from the pipeline we acquired in our merger with Sirius Laboratories, Inc. in March 2006. We believe that our ability to bring ClindaReach to patients and their physicians underscores both the synergistic opportunities we anticipated with our merger and our commitment to serving patients as a leading provider of dermatological pharmaceuticals through our expanding product portfolio."

About ClindaReach™

ClindaReach is indicated for the treatment of acne vulgaris. Each treatment package includes:

- EasyReach™ Applicator, ergonomically designed wand with a multi-directional pivotal head

- ClindaReach™ medicated pledgets (pads containing clindamycin phosphate topical solution USP, 1%)

- EasyCling™ Appliques firmly affix the clindamycin pledgets (medicated pads) to the applicator arm to easily reach the affected area

- EasyCleanse™ unmedicated pads

About Acne

Acne is the most common skin disease in the U.S., affecting 40-50 million people of all races and ages. However, it is most common in teenagers and young adults. About 85% of people between the ages of 12 and 24 develop acne. In the most severe cases, the lesions are large and painful. According to researchers, more than 40% of adolescents have acne severe enough by their mid-teens to require medical treatment from a doctor. For most people, acne disappears by age 30, but some people in their forties and fifties still develop acne. (U.S. National Institutes of Health)

Dermatologists indicate that it can be a challenge to find the right topical treatment for acne on the hard-to-reach areas because patients are often unable to apply medication themselves.

Studies have shown that poor treatment compliance is a well recognized problem for patients with acne that can impact the efficacy of treatment. It is believed that 30-40% of patients using topical formulations fail to comply with their treatment regimens. Other studies have shown that acne can have considerable effects on self-image, body-image, and psychological well-being.

About DUSA Pharmaceuticals, Inc.

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReach™, Nicomide® and the AVAR® line. DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, MA. Please visit the company's website at www.dusapharma.com for more information.

Forward Looking Statements

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to management's beliefs concerning synergies of the merger with Sirius, commitment to patients, an expanding product portfolio, and the percentage of compliant patients. Furthermore, the factors that may cause differing results include the ability to penetrate the market, the regulatory process, sufficient funding, maintenance of DUSA's patent portfolio, reliance on third parties, and other risks identified in DUSA's SEC filings from time to time, including its annual report on Form 10-K for the year ended December 31, 2006.

(i) Dr. Mark S. Nestor is a consultant to the company.

Contact Information

  • DUSA Pharmaceuticals, Inc.
    Media Contact:
    Kathleen O'Donnell
    (617) 512-4519
    DUSA Pharmaceuticals, Inc.
    Susan Laine
    (301) 530-6231
    Website: www.dusapharma.com